ADMA Biologics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2004-01-01
- Employees
- 624
- Market Cap
- $4B
- Website
- http://www.admabiologics.com
An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD)
- Conditions
- Primary Immune Deficiency
- Interventions
- Biological: Asceniv™
- First Posted Date
- 2021-10-07
- Last Posted Date
- 2022-09-16
- Lead Sponsor
- ADMA Biologics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05070455
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸Immunoe Research Centers, Centennial, Colorado, United States
🇺🇸University of Utah, Salt Lake City, Utah, United States
Study to Evaluate Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Subjects Aged 2 to 16
- Conditions
- Humoral Immune Response
- Interventions
- Biological: Bivigam
- First Posted Date
- 2017-05-24
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- ADMA Biologics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT03164967
- Locations
- 🇺🇸
IMMUNOe Research Centers, Centennial, Colorado, United States
🇺🇸Ohio Clinical Research Associates, Mayfield Heights, Ohio, United States
🇺🇸Allergy Associates of the Palm Beaches, North Palm Beach, Florida, United States
A Study About Low Blood Pressure in Patients With Primary Immunodeficiency Disease Treated With Immune Globulin Products
- Conditions
- Primary Immune Deficiency Disorder
- Interventions
- Biological: OtherBiological: Bivigam
- First Posted Date
- 2017-01-31
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- ADMA Biologics, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT03037359
- Locations
- 🇺🇸
Discovery Clinical Trials, Dallas, Texas, United States
🇺🇸Lysosomal Rare Disorders Research & Treatment Center, Fairfax, Virginia, United States
🇺🇸Allergy Asthma & Immunology Relief, Charlotte, North Carolina, United States
Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)
- Conditions
- Primary Immune Deficiency Disorder
- Interventions
- Biological: RI-002
- First Posted Date
- 2013-03-20
- Last Posted Date
- 2016-10-05
- Lead Sponsor
- ADMA Biologics, Inc.
- Target Recruit Count
- 59
- Registration Number
- NCT01814800
- Locations
- 🇺🇸
Asthma & Immunology Associates, Omaha, Nebraska, United States
🇺🇸Allergy Associates of the Palm Beaches, P.A., North Palm Beach, Florida, United States
🇺🇸Family Allergy Center, PC, Atlanta, Georgia, United States
RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness
- Conditions
- Upper Respiratory Tract InfectionLower Respiratory Tract Infection
- Interventions
- Biological: RI-001
- First Posted Date
- 2008-03-10
- Last Posted Date
- 2013-04-24
- Lead Sponsor
- ADMA Biologics, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT00632463
- Locations
- 🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸All Children's Hospital, St. Petersburg, Florida, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)
- Conditions
- Primary Immune Deficiency Disorders (PIDD)
- Interventions
- Biological: Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]
- First Posted Date
- 2007-10-03
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- ADMA Biologics, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT00538915
- Locations
- 🇺🇸
Women's and Children's Hospital of Buffalo, Buffalo, New York, United States
🇺🇸University of Alabama, Birmingham, Alabama, United States
🇺🇸1st Allergy and Clinical Resaerch center, Centennial, Colorado, United States
Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation
- Conditions
- Sequelae of Viral HepatitisTransplantation InfectionEvidence of Liver Transplantation
- Interventions
- Biological: Hepatitis C Immune Globulin Intravenous (Human) 5%
- First Posted Date
- 2007-05-16
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- ADMA Biologics, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT00473824
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States